



# CANCER CARE AT THE CROSSROADS

 **NY - March 15, 2024**

**A One-Day International Summit on Innovation, Clinical Benefit and Cost**

## Meet the Sponsors



8:00am to 8:20am

## Welcome and Opening Remarks

Setting the Stage for the Day



**TOM MANIATIS, PHD**

Evnin Family Scientific Director and Chief Executive Officer, *New York Genome Center* Isidore S. Edleman Professor of Biochemistry and Molecular Biophysics, *Columbia University*



**MIKE MEYER**

President and Founder,  
*Meyer Consulting*



**CLIFFORD A. HUDIS, MD, FACP, FASCO**

CEO,  
*American Society of Clinical Oncology (ASCO)*

Opening Remarks

8:20am to 9:30am

## Roundtable 1

Cancer Care Through the Lens of Health Plans, Academic Centers, Employers, Pharma and Provider Groups



Moderator

**CLIFFORD A. HUDIS, MD, FACP, FASCO**

CEO,  
*American Society of Clinical Oncology (ASCO)*



Panelist

**JIM FITTERLING**

Chairman and CEO,  
*Dow*



Panelist

**CINDY PERETTIE**

Executive Vice President,  
*Kite Pharma*



Panelist

**ERIC WINER, MD**

Director,  
*Yale Comprehensive Cancer Center*  
and Physician-in-Chief  
*Smilow Cancer Hospital*



Panelist

**BRYONY WINN**

President Health Solutions  
*Elevance Health*

Roundtable 1

9:30am to 10:40am

## Roundtable 2

The Future of Cancer Science



Moderator  
**JAMES GULLEY, MD, PhD**  
Co-Director Center for Immuno-  
Oncology, CCR, NCI, NIH  
& Clinical Director, National Cancer  
Institute, NIH



Panelist  
**WILLIAM OH, MD**  
Chief Medical Officer,  
*The Prostate Cancer Foundation*



Panelist  
**MACE ROTHENBERG, MD**  
President and Executive Director,  
*Museum of Medicine and Biomedical  
Discovery*  
Former Chief Medical Officer, Pfizer



Panelist  
**MICHEL SADELAIN, MD,  
PHD**  
Director, Center for Cell Engineering,  
*Memorial Sloan Kettering  
Cancer Center*



Panelist  
**LILLIAN SIU, MD, FRCPC**  
Professor, *University of Toronto*,  
Medical Oncologist, and Director,  
Phase 1 Program, *Princess Margaret  
Cancer Centre*

10:40am to 11:00am

## Break

11:00am to 12:10pm

## Roundtable 3

Improving Patient Outcomes Through Innovations in Care Delivery



Moderator  
**JAMIE REEDY, MD, MPH**  
Chief Population Health Officer and  
Senior Vice President, Health  
Solutions, *Horizon Blue Cross Blue  
Shield of New Jersey*



Panelist  
**EDWARD J. LICITRA, MD,  
PhD**  
Chief Executive Officer,  
*Astera Health Partners/Astera Cancer  
Care*



Panelist  
**RUBEN MESA, MD**  
President, *Atrium Health Levine  
Cancer*  
Executive Director,  
*Atrium Health Wake Forest Baptist  
Comprehensive Cancer Center*



Panelist  
**RAPHAEL RAKOWSKI**  
Executive Chair and Co-Founder,  
*Medically Home*



Panelist  
**RICHARD SULLIVAN, MD,  
PhD**  
Director, *Institute for Cancer Policy*,  
Professor of Cancer & Global Health,  
*King's College, London*



1:15pm to 2:25pm

**Roundtable 4**

The Challenges Facing Health Plans, Pharma, Providers and Government in Financing Expensive Innovative Cancer Treatment



Moderator

**JON ROCKOFF**Health Business Editor and Deputy  
Coverage Chief for Health and  
Science, *The Wall Street Journal*

Panelist

**PETER ADAMSON, MD**Global Head, Oncology Development  
*Sanofi*

Panelist

**ELI CASDIN**Chief Investment Officer and  
Founder,  
*Casdin Capital*

Panelist

**JOANNE CONROY, MD**President and CEO,  
*Dartmouth Health*

Panelist

**JAEWON RYU, MD, JD**President and Chief Executive Officer,  
*Geisinger*

Roundtable 4

2:25pm to 2:45pm

**Break**

2:45pm to 3:55pm

**Roundtable 5**

The Future Relationship Among Primary Care, Oncologists, Health Systems, Academics and Pharma



Moderator

**KAREN KNUDSEN, MBA,  
PhD**Chief Executive Officer, *American  
Cancer Society, Inc. and American  
Cancer Society Cancer Action  
Network*

Panelist

**TIM BARRY**Co-Founder and CEO,  
*VillageMD*

Panelist

**ALEXANDER EGGERMONT,  
MD, PhD**CSO, *Utrecht*  
Former Director, *Gustave Roussy*

Panelist

**DEEPA KUMARAIH, MD,  
MBA**Senior Vice President &  
Chief Medical Officer  
*NewYork Presbyterian*

Panelist

**ROBERT LOBERG, PhD**  
VP, Disease Area Lifecycle Leader,  
*Roche Sequencing Solutions*

Roundtable 5

# Panelist Bios



## **PETER C. ADAMSON, MD**

Global Head, Oncology Development  
*Sanofi*

Peter C. Adamson, MD is Global Development Therapeutic Area Head, Oncology and Pediatric Innovation at Sanofi. Dr. Adamson leads global cancer drug development for Sanofi and works with leaders across Sanofi's therapeutic areas to further pediatric drug development efforts. He is also pioneering Sanofi's Corporate Social Responsibility Flagship Program for childhood cancer.

Prior to this, Dr. Adamson served as Chair of the Children's Oncology Group, a National Cancer Institute supported international consortium of more than 220 childhood centers. Dr. Adamson, currently Emeritus Professor of Pediatrics and Pharmacology at the Perelman School of Medicine, is Board Certified in Pediatric Hematology/Oncology and Clinical Pharmacology. He was appointed by President Obama and served on his National Cancer Advisory Board. Dr. Adamson also served on the Blue-Ribbon Panel for the Beau Biden National Cancer Moonshot Initiative.



## **TIM BARRY**

Co-Founder and Chief Executive Officer  
*VillageMD*

Tim Barry is CEO, Co-Founder, Chair of VillageMD. In this role, Tim evangelizes the vision of a primary care-led healthcare delivery system that brings superior clinical results to the communities where VillageMD works. Through Village Medical, Village Medical at Home, Summit Health, CityMD and other practices, VillageMD serves millions of patients throughout their lives, wherever and whenever they need care. Under Tim's leadership, VillageMD has a dedicated workforce of more than 20,000 operators from 680 practice locations in 26 markets.

Prior to VillageMD, Tim has held numerous senior executive positions across the healthcare spectrum, all focused on empowering healthcare providers to bring value to the market through accountable care and population management. Tim earned degrees from both Cornell University and Michigan State University, and now resides in the Chicagoland area.



## **ELI CASDIN**

Chief Investment Officer and Founder  
*Casdin Capital*

Eli Casdin founded Casdin Capital in 2011 and serves as Chief Investment Officer and Founder. Casdin Capital engages as productive investor-partners, helping to fuel the visions of industry leaders by adding expertise and experience to their funding. Focused on emergent technologies in Life Sciences for more than two decades, Mr. Casdin has been active in both private and public capital markets, following a passion for analyzing and investing in new technologies and business models within the Life Sciences and healthcare industry.

Prior to founding Casdin Capital, Mr. Casdin served as vice president at Alliance Bernstein's thematic investment arm, focusing personally on new technologies for the life sciences and healthcare sectors. While there he authored the 2011 black book, "The Dawn of Molecular Medicine," detailing the (then) early-yet-accelerating wave of innovations transforming healthcare and creating opportunity for investors from testing to targeted medicine, diagnostics to industrial agriculture. Earlier, he worked as a financial analyst at Bear Stearns and Cooper Hill Partners, a healthcare- focused investment firm.

Mr. Casdin earned a B.S. from Columbia University and an MBA from Columbia Business School. Today, he serves as a director or an observer on various boards for a number of public and private life sciences companies, trade groups and academic institutes including Rockefeller University, the New York Genome Center Board and The Columbia University School of General Studies Board of Visitors.



## JOANNE CONROY, MD

President and CEO  
Dartmouth Health

Joanne M. Conroy, MD, has led Dartmouth Health as chief executive officer and president since 2017, overseeing the management of the state's only academic health system and largest private employer in a complex and rapidly evolving healthcare landscape.

Under Conroy's leadership the system's flagship hospital, Dartmouth Hitchcock Medical Center in Lebanon, NH, is regularly ranked as the #1 hospital in New Hampshire by U.S. News & World Report.

Conroy also has moved Dartmouth Health to continue broadening its service to New Hampshire and Vermont communities through partnerships and collaborations in both states. The Dartmouth Health system now includes four hospitals and a home health agency, and a longstanding, strong relationship with the Geisel School of Medicine at Dartmouth continues to provide key academic and research collaborations to train the next generation of physicians.

Conroy has long been a vocal advocate for increasing the role of women in leadership and is often singled out as a role model for other women who aspire to become leaders and agents for positive change in healthcare.

Conroy was named to the American Hospital Association's Board of Trustees in 2019, and in 2022 was named Chair-Elect Designate, to serve as chair of the AHA Board in 2024.

In December 2022, Conroy was ranked #18 on Modern Healthcare magazine's list of "100 Most Influential People in Healthcare". Other recent national and regional awards and honors of note include being named to Becker's Hospital Review's "Top 113 Great Leaders in Health care" list and the 2021 Citizen of the Year by the New Hampshire Union Leader.

Conroy received her undergraduate degree in chemistry from Dartmouth College and earned her medical degree at the Medical University of South Carolina. She is board certified with the American Board of Anesthesiologists.



## ALEXANDER EGGERMONT, MD, PhD

CSO, *Utrecht University*  
Former Director, *Gustave Roussy*

Past Director General of the Gustave Roussy Cancer Institute & Emeritus Full Professor of Oncology (2012-20)(Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Emeritus Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.

Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models, drug development.

Scientific Output: is the author or co-author of > 900 peer-reviewed publications, book chapters and monographs. More than 35 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-Index: 132; > 90.000 citations (Google Scholar)

International Functions:

Deutsche Krebshilfe: Coordinator German CCC Network Program European Academy of Cancer Sciences: President, 2010-2020 Cancer Core Europe President – 2014-2020

ECCO: Past President EORTC: Past President ASCO: Past Board Member (Surgery Chair) and JCO Editorial Board AACR: Past Deputy Editor of Clinical Cancer Research (2001-2009) European Journal of Cancer: Editor-in-Chief since 2011

Societal Awards:

Legion d'Honneur, France (2015)



## JIM FITTERLING

Chairman & CEO  
Dow

Jim Fitterling is the chair and chief executive officer of Dow, a global materials science company with 2022 sales of \$57 billion.

He has played a key role in the Company's transformation from lower-margin, commodity businesses to one more deeply focused on higher-growth, consumer demand-driven markets that value innovation - with the goal of creating the most innovative, customer-centric, inclusive and sustainable materials science company in the world.

During his 39-year career at Dow, Fitterling has held leadership positions in many of the Company's business units, in corporate development and in business operations.

A passionate advocate for inclusion and diversity, Fitterling leads Dow's drive to diversify its global talent. He serves as Executive Sponsor of Dow's Global African Affinity Network and is widely recognized for his work supporting LGBT non-discrimination and LGBT+ workplace equality. In 2018, he was named #1 LGBT+ Executive on the "OUTstanding in Business" list by INvolve. In 2021, he was inducted into the OUTstanding Hall of Fame. He joined the Out Leadership Global Advisory Board in 2019.

Fitterling is Chair of the Board of Directors of the National Association of Manufacturers; sits on the Board of Directors for 3M, The American Chemistry Council, Catalyst, the U.S.-China Business Council, Business Roundtable, and the Detroit Economic Club. In addition, he's a member of the American Heart Association's CEO Roundtable, the Business Council, the World Economic Forum's International Business Council, and the Dean's Engineering Advisory Council for the University of Missouri's College of Engineering.

# Panelist Bios



## **JAMES L. GULLEY, MD, PhD, FACP**

Co-Director Center for Immuno-Oncology  
*CCR, NCI, NIH*  
& Clinical Director  
*National Cancer Institute, NIH*

Dr. James Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program he completed a dissertation on tumor immunology. Dr. Gulley completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.

Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as Principal Investigator or Associate Investigator on more than 200 trials including dozens of first-in-human studies. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents, and the combination of immunotherapy with other treatment strategies. In particular, he has played a central role in the clinical development of a number of vaccines and antibodies including avelumab (Bavencio) and bintrafusp alfa. His clinical studies led to the approval of avelumab in 2017.

Dr. Gulley has authored more than 350 scientific papers and book chapters, edited four books, and has made hundreds of presentations at national and international meetings.



## **CLIFFORD A. HUDIS, MD, FACP, FASCO**

Chief Executive Officer  
*American Society of Clinical Oncology (ASCO)*

Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society's 50th anniversary year (2013-14).

Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board's strategic goals through research, education, and promotion of the highest quality, equitable patient care by the Society's nearly 50,000 members.



## **KAREN E. KNUDSEN, MBA, PhD**

Chief Executive Officer  
*American Cancer Society, Inc. and*  
*American Cancer Society Cancer Action Network*

Karen E. Knudsen, MBA PhD, is the CEO of both the American Cancer Society (ACS) and the American Cancer Society Cancer Action Network (ACS CAN). As an internationally recognized oncology leader, healthcare executive, and advocate, Dr. Knudsen guides both organizations toward the goal of improving the lives of cancer patients and their families.

Prior to joining ACS, Dr. Knudsen served as EVP of Oncology Services and enterprise director for Sidney Kimmel Cancer Center - Jefferson Health, one of only 71 National Cancer Institute-designated cancer centers. She also served as president for the Association of American Cancer Institutes (AACI), which is an important voice in advocating for funding for cancer research and access to care, including patient access to research innovations.

Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the nation. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards. She previously served on the board of directors of the American Association for Cancer Research (AACR).





## **DEEPA KUMARAIAH, MD, MBA**

Senior Vice President &  
Chief Medical Officer  
*NewYork Presbyterian*

Deepa Kumaraiah, M.D., M.B.A. is Senior Vice President and Chief Medical Officer at NewYork-Presbyterian. In this role, she oversees the Clinical Service Lines, where she provides leadership, management, and strategic vision for the growth and integration of those efforts across all 10 NewYork-Presbyterian hospitals and the NYP Medical Groups. She also oversees both enterprise-wide medical affairs and the integrated Quality and Performance Improvement program. Dr. Kumaraiah joined NYP in 2012 and previously served as the Senior Vice President, Service Line Integration and Chief Physician, NewYork-Presbyterian Medical Groups; and before that, as Vice President and Associate Chief Medical Officer of Service Lines and Clinical Strategy. She is an Assistant Clinical Professor of Medicine at Columbia University Irving Medical Center, where she continues to practice in the cardiac intensive care unit. Prior to joining NYP, Dr. Kumaraiah was a health care consultant at McKinsey and Company, focused on health care system transformation. She completed her cardiovascular fellowship training at NYP/CUIMC and her internship and residency at Massachusetts General Hospital. She earned her medical degree from the University of Pennsylvania, her Masters of Business Administration from the Wharton School, and her Sc.B. from Brown University.



## **EDWARD J. LICITRA, MD, PhD**

Chief Executive Officer  
*Astera Health Partners/Astera Cancer Care*

Edward J. Licitra, MD, PhD received his PhD in Organic Chemistry and Molecular Biology from the Massachusetts Institute of Technology, where he was a National Cancer Institute Predoctoral Fellow. He is a graduate of the University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School along with internship and residency there. Dr. Licitra was the recipient of the Robert Wood Johnson Medical School Research Award and was designated as the Medical School's Department of Internal Medicine Outstanding Resident. He then completed a fellowship in Medical Oncology at the Cancer Institute of New Jersey and was an attending physician at Memorial Sloan Kettering Cancer Center. He then entered private practice in New Jersey in 2006 and has since been developing a high-quality cancer care delivery platform in the community. He is certified by the American Board of Internal Medicine in Medical Oncology. Dr. Licitra has been chosen as a Top Doctor in Oncology & Hematology by New Jersey Monthly magazine. He serves as Chief Executive Officer of Astera Health Partners. He is on the Board of Directors of OneOncology, The Community Oncology Alliance (COA) and the ION Advisory Board.



## **ROBERT LOBERG, PhD**

VP and Lifecycle Leader, Oncology & Genetics  
*Roche Diagnostics*

Robert Loberg is Vice President and Lifecycle leader, Oncology & Genetics at Roche Diagnostics. In his role, Robert oversees development and commercialization of the next generation sequencing & PCR portfolio assay and menu content. In addition, Robert heads the molecular PharmaPartnering & Services Business overseeing the Roche San Jose CAP/CLIA laboratory.

Robert has experience across a range of R&D and commercial activities at both BioPharma and Diagnostics companies. Prior to his joining Roche, Robert spent 13 years at Amgen in various roles ending his time at Amgen leading the Clinical Biomarker and Diagnostics efforts within iR&D. His experience in development, regulatory approval, and market access has led to a record of delivering strategies that support a broad portfolio of pharmaceutical and diagnostic products. With >50 peer-reviewed publications and considerable hands-on lab work, Robert has demonstrated a passion for translational research and its applications in cancer therapeutics.

Robert received his Ph.D in Physiology from the University of Michigan where he also served as an Assistant Professor holding joint appointments in the Department of Internal Medicine and Department of Urology.

# Panelist Bios



## **TOM MANIATIS, PHD**

Evnin Family Scientific Director and Chief Executive Officer  
*New York Genome Center*

Isidore S. Edelman Professor of Biochemistry & Molecular Biophysics  
*Columbia University*

Dr. Maniatis leads the research and operational activities of the New York Genome Center (NYGC), which focus on the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative diseases, and neuropsychiatric diseases. He also directs NYGC's faculty, who lead independent research labs based at the Center. All of the core faculty members hold tenure-track joint appointments with one of the Center's member institutions. This arrangement has been a driving force in connecting the NYGC with its founding members.

Dr. Maniatis is recognized as one of the pioneers of modern molecular biology, having led the development of recombinant DNA methods and their application to the study of the mechanisms of gene regulation. He co-authored the definitive laboratory manual on genetic engineering, entitled the *Molecular Cloning Manual*, along with Joe Sambrook and Ed Fritsch in 1982. This three-volume manual, published by the Cold Spring Harbor Laboratory, set a standard for international dissemination of recombinant DNA methods. Dr. Maniatis' research has led to major advances in understanding the mechanisms of gene expression at the level of RNA transcription and splicing. His current research is focused on the role of single cell diversity in neural connectivity, and on the molecular mechanisms that underlie the neurodegenerative disease ALS (Lou Gehrig's Disease).

Dr. Maniatis' research contributions have been acknowledged by membership in the U.S. National Academy of Sciences and the U.S. National Academy of Medicine, and by numerous awards, including the Eli Lilly Research Award in Microbiology and Immunology, the Novartis Drew Award in Biomedical Research, the Richard Lounsbery Award for Biology and Medicine, and the Lasker Koshland Special Achievement Award in Medical Science. He has received honorary PhD degrees from the Cold Spring Harbor Graduate School, the University of Athens, and the Rockefeller University.



## **RUBEN MESA, MD**

President, *Atrium Health Levine Cancer*  
Executive Director, *Atrium Health Wake Forest Baptist Comprehensive Cancer Center*

Dr. Mesa is the President of Atrium Health Levine Cancer, the Executive Director of the NCI Comprehensive Cancer based at Wake Forest Baptist; the Vice Dean for cancer programs at Wake Forest School of Medicine Enterprise Cancer Service Line Atrium Health and Senior Vice President for Atrium Health where he oversees all efforts for cancer practice, education and research across Atrium Health (the Southeast Region for Advocate Health the 5<sup>th</sup> largest health system in the USA). From 2017-2023 Mesa was the Executive Director of the NCI Designated Mays Cancer Center at UT Health San Antonio MD Anderson where he developed and grew the cancer service line, co-led the development and construction of a new cancer focused hospital, grew cancer faculty, peer reviewed funded research and successfully renewed the NCI designation in 2020. Mesa practiced hematology at Mayo Clinic (MN 2002-2009, AZ 2009-2017) and was Chair of Hematology & Medical Oncology and Deputy Director of the Mayo Clinic Comprehensive Cancer Center.

Mesa is an international expert in hematologic cancers, who has dedicated his life's work to research and drug development for myeloproliferative neoplasms and led/co-led the development of six drugs that have been FDA approved for myeloproliferative neoplasms and was the inaugural panel chair of the NCCN guideline panel for the first USA guidelines for MPNS. Mesa is passionate about advancing cancer health equity and increasing minority patients' participation in cancer clinical trials, implement a mandate that each new trial at the Mays Cancer Center had a minority accrual plan, and in March 2022, he testified on the importance of clinical trial diversity before the House Committee on Energy and Commerce. Mesa also co-led the Mays Cancer Center's biennial Advancing the Science of Cancer in Latinos Conference held in San Antonio.



## **MIKE MEYER**

Founder and President  
*Meyer Consulting*

Mike Meyer is an entrepreneur, author, health care expert, and founder and host of the CCX Cancer Summit held each year in New York City. He is the President of Meyer Consulting. Early in the pandemic, he coauthored an op-ed in the Wall Street Journal titled Medical Lockdown will Cause a Disease Surge, which proved remarkably accurate. He is known for his work with leading health systems, academic medical centers and health care companies. Over the years, he has built or helped grow multiple health care companies.

Meyer founded Meyer Consulting in 2007 to offer healthcare organizations a consulting firm that has a unique business model encompassing executive search, strategic consulting, and human capital consulting. Meyer's current and former clients include Memorial Sloan Kettering Cancer Center, Mayo Clinic, Blue Cross Blue Shield Association, Horizon Blue Cross Blue Shield NJ, Pfizer, MD Anderson Cancer Center, Summit Medical Group, California Association of Health Plans, WIN Consortium for Personalized Cancer Medicine and numerous other academic centers, large providers, physician groups and other not-for-profit health care organizations.

Meyer's early career was as vice president in charge of the New York office of Amherst Associates, which went public in 1981. He subsequently became a senior partner in Witt Kieffer before founding Meyer Consulting in 2007. Meyer founded Cancer Care at the Crossroads (CCX) Summit in 2016. This one-of-a-kind event brings together senior health care executives from the US and international. In 2019 Meyer Consulting's executive search practice was acquired by Westwood & Wilshire, one of the premier firms in life sciences and technology.

Meyer was a board member of Summit Select, part of Summit Medical Group which merged with CityMD, creating one of the largest private physician groups in the U.S., with support from Warburg Pincus. He cofounded the Institute for Mental Health Research ([www.imhr.org](http://www.imhr.org)) and is a board member of the Human Health and Research Foundation (<http://hherf.org>). He has been widely quoted on healthcare, oncology, mental health and retiree topics in healthcare and business publications. He is the author of Catastrophic Illness and Catastrophic Health Insurance published by the Heritage Foundation, and coauthor of Destination Southwest, a Guide to Retiring and Wintering in Arizona.



## **WILLIAM OH, MD**

CMO  
*The Prostate Cancer Foundation*

Dr. William K. Oh is Chief Medical Officer at the Prostate Cancer Foundation (PCF) and a Clinical Professor of Medicine in the Division of Hematology/Medical Oncology at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies. Prior to joining PCF, he was the Chief Medical Officer at Sema4, a health intelligence company. From 2009-2020, he was Chief of the Division of Hematology/Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at Mount Sinai. He spent 14 years at Harvard Medical School and Dana-Farber Cancer Institute, including service as Clinical Director of GU Oncology and Associate Professor of Medicine. He has authored more than 350 original articles, reviews and book chapters on topics relating to prostate, renal, bladder and testicular cancers. He has edited books on prostate cancer and has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS) and the American Urological Association (AUA), including the Guidelines Committee for Castration Resistant Prostate Cancer.



## **CINDY PERETTIE**

Executive Vice President  
*Kite Pharma*

Cindy Perettie serves as Executive Vice President of Kite, a Gilead Company, and is responsible for overseeing the cell therapy business.

Cindy joined Kite in 2023 with more than 25 years of scientific and commercial leadership experience in global biopharmaceutical organizations. Most recently, she served as Head of Roche Molecular Lab Solutions where she oversaw the PCR (polymerase chain reaction) and Sequencing Business. Prior to that, she was Chief Executive Officer at Foundation Medicine. Before joining Foundation Medicine, Cindy was Head of Global Oncology Strategy at Roche's Oncology Unit. In 2012, Cindy joined Sarah Cannon Research Institute as President of Global Development Innovations where she gained invaluable insights into the day-to-day care of people living with cancer. She started her career at Johns Hopkins University as a senior research associate.

She holds an MBA from Saint Mary's College of California and a bachelor's degree in biology with a minor in chemistry from The State University of New York at Potsdam.



## **RAPHAEL RAKOWSKI**

Co-Founder, Executive Chairman  
*Medically Home*

Mr. Rakowski has had a highly diverse 45-year career in engineering, management consulting, private equity, consumer brand marketing, health care executive leadership, and entrepreneurial start-ups in healthcare services and renewable resources. This diversity has fueled a unique perspective on social, economic, healthcare and political challenges we face as a global community. He is a frequent public speaker and fierce advocate for patient-centric healthcare and the global decentralization of healthcare delivery. He has worked and lived extensively abroad (Brazil, Germany, India, and Japan) and has a global view of business, education, and social interdependency. He is currently the Executive Chairman and Co-Founder of Medically Home, the pioneering firm that has been driving the market to decentralize healthcare delivery. His extensive experience includes his time as President of American Healthways, where he led a strategy to rethink population health for the 3M patients being served with that platform.

Mr. Rakowski is father of four (spectacular) children that have blessed him with grandchildren that fill him with joy and a great deal of learning. He holds a bachelor's degree in political science from Lehman College which is part of the City University of New York and was a Rotary Foundation fellow in 1974 in Munich, West Germany, where he studied the Holocaust (both of his parents remarkably survived six years in the Auschwitz, Bergen Belsen and Dachau concentration Camps). Their experience has been the driving force in his perspective and passion for transformation. He frequently teaches entrepreneurship in public and private universities. In 2009, he was featured in a documentary film ("Mr. Rakowski") about his life with his father (<http://www.Mrrakowski.com>).

# Panelist Bios



## JAMIE REEDY, MD, MPH

Chief Population Health Officer and  
Senior Vice President, Health Solutions  
*Horizon Blue Cross Blue Shield of New Jersey*

Dr. Reedy is accountable for provider network management, operations and strategy, clinical transformation and provider engagement, clinical and predictive analytics, medical management (UM, CM, DM), quality management and health equity.

Prior to joining Horizon BCBSNJ in September 2022, Dr. Reedy was the Chief of Population Health for Summit Health, one of the largest physician-led multispecialty groups/physician management companies in the country. Dr. Reedy was responsible for building a comprehensive value-based care model that is considered one of the most successful and innovative of its kind. She previously served as Senior Vice President and Medical Director of Population Health and Quality at Summit Medical Group and Summit Health Management and was also formerly Chief of Hospital Medicine and Post-Acute Care.

Prior to joining Summit in 2011, Dr. Reedy was Medical Director, Compliance Officer and a practicing physician with Paramount Medical Group/Westfield Family Practice in Westfield, NJ. In that role, she led an initiative to become a Level-3 National Committee for Quality Assurance recognized Patient-Centered Medical Home.

Dr. Reedy has a bachelor's degree from NYU and a master's degree in Health Policy and Management from the Johns Hopkins University School of Hygiene and Public Health. She earned her medical degree at the Robert Wood Johnson Medical School. She also completed her internship and a residency in Family Medicine at Robert Wood Johnson. She is board-certified by the American Board of Family Medicine and a Diplomate of the National Board of Medical Examiners.

Dr. Reedy has held board positions with America's Physician Groups, the National Association of ACOs, Paramount Medical Group and the NJ Academy of Family Physicians. She is also a former Chair of the Academy's Government Affairs Committee and a former policy fellow and advisor for the NJ State Senate. Dr. Reedy is a recognized thought leader who has been a featured speaker at many national conferences.



## JON ROCKOFF

Health Business Editor and Deputy Coverage Chief for Health and  
Science  
*The Wall Street Journal*

Jonathan D. Rockoff is the Health Business Editor at The Wall Street Journal, as well as its Deputy Coverage Chief for Health and Science. Based in New York City, he edits a group of reporters that write about pharmaceutical companies, health insurers and hospitals, while helping oversee science, medicine and public-health reporting. Previously for the newspaper, Jonathan reported on the pharmaceutical and biotechnology industries. He was a member of a team of reporters that was a finalist for the Pulitzer Prize for their coverage of drug pricing. Jonathan has also worked at The Baltimore Sun and The Providence Journal. He is a graduate of Princeton University and the University of Virginia School of Law.



## MACE ROTHENBERG, MD

President and Executive Director  
*Museum of Medicine and Biomedical Discovery*  
Former Chief Medical Officer, *Pfizer*

Mace L. Rothenberg, MD is President and Executive Director of the Museum of Medicine and Biomedical Discovery. He has more than 30 years of experience in academia, industry, and the not-for-profit sector. Prior to his current role, Dr. Rothenberg was Chief Medical Officer of Pfizer from 2019 to 2021, during which time the company developed and received Emergency Use Authorization for Comirnaty, its Covid-19 vaccine. Prior to that role, Mace was Pfizer's Chief Development Officer/Head of Clinical Development & Medical Affairs for Pfizer Oncology. During his 10 years in that role, his organization developed and obtained regulatory approval for 11 new cancer medicines including first-in-class medicines Ibrance (palbociclib) for patients with HR+/HER2- advanced breast cancer and Xalkori (crizotinib) for patients with ALK+ non-small cell lung cancer. Prior to joining Pfizer, Dr. Rothenberg was Professor of Medicine at Vanderbilt University and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center from 1998 to 2008.

Mace is an independent board member and consultant for several biotech companies and sits on the board of several not-for-profit organizations.





## **JAEWON RYU, MD, JD**

President and Chief Executive Officer  
*Geisinger*

Jaewon Ryu, MD, JD, is the President and CEO of Geisinger, an integrated delivery system with a clinical enterprise, health plan, the Geisinger Commonwealth School of Medicine, and research and innovation institutes. Dr. Ryu came to Geisinger in 2016 from Humana, where he was responsible for the company's care delivery assets, and previously, he held various leadership roles at the University of Illinois Hospital & Health Sciences System, Kaiser Permanente, and in government at the Centers for Medicare and Medicaid Services and at the Department of Veterans Affairs. He started his career as a practicing corporate healthcare attorney.

Dr. Ryu serves on the Medicare Payment Advisory Commission (MedPAC), a body legislatively tasked with advising Congress on policies governing health plans and providers serving Medicare beneficiaries. He also serves on the boards of various organizations including the National Committee for Quality Assurance (NCQA) and the Commonwealth Fund.

Dr. Ryu earned his B.A. from Yale University and his M.D. and J.D. from the University of Chicago. He completed his residency training in emergency medicine at Harbor-UCLA Medical Center.



## **MICHEL SADELAIN, MD, PhD**

Director, Center for Cell Engineering  
*Memorial Sloan Kettering Cancer Center*

Dr. Sadelain has made major contributions to the generation and optimization of CAR T cells to treat cancer, as well as the development of stem cell therapies for blood disorders. Dr. Sadelain's work has focused on developing novel strategies to extend survival of CART cells in the body and enable T cells with increased potency to overcome the resistance imposed by tumor and other cells in the tumor microenvironment.

Dr. Sadelain is founding director of the Center for Cell Engineering and head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center (MSKCC), where he holds the Stephen and Barbara Friedman Chair. Dr. Sadelain is also a member of the departments of medicine and pediatrics at Memorial Hospital and the molecular pharmacology and chemistry program of the Sloan Kettering Institute.

Dr. Sadelain received his MD from the University of Paris, France, in 1984 and his PhD from the University of Alberta, Canada, in 1989. After completing a clinical residency at the Centre Hospitalier Universitaire Saint-Antoine in Paris, Dr. Sadelain carried out a postdoctoral fellowship with Richard Mulligan, PhD, at the Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, before joining MSKCC in 1994 as an assistant member. He has authored more than 150 scientific papers and book chapters.



## **LILLIAN SIU, MD, FRCPC**

Professor, *University of Toronto*  
Medical Oncologist and Director of Phase 1 Trials Program, BMO Chair in Precision Genomics,  
*Princess Margaret Cancer Centre*

Dr. Siu is a senior medical oncologist at Princess Margaret Cancer Centre since 1998 and has been a Professor of Medicine at the University of Toronto since 2009. She is the Director of the Phase I Program and Co-Director of the Bras and Family Drug Development Program at Princess Margaret Cancer Centre and holds the BMO Chair in Precision Genomics (2016-2026). She is also the Clinical Lead for the Tumor Immunotherapy Program at Princess Margaret Cancer Centre. Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016); she also served on the American Association for Cancer Research (AACR) Board of Directors for a three-year term (2017-2020).

Dr. Siu's major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. She is the Principal Investigator of a phase I cooperative agreement UM1 award sponsored by the United States National Cancer Institute. In addition to her active research in early phase clinical trials, she has been leading genomics initiatives and immuno-oncology trials at the Princess Margaret Cancer Centre. Together, the three programs of drug development, cancer genomics and tumor immunotherapy form a triad of synergy that supports the institution's core vision to deliver precision cancer medicine. Internationally, Dr. Siu was the recipient of the US NCI Michael C. Christian Award in Oncology Drug Development in 2010. She has been awarded the TAT 2020 Honorary Award for contributions in the development of anticancer drugs. Dr. Siu has published over 370 peer-reviewed manuscripts, and she is currently the co-Editor-in-Chief for AACR's newest journal *Cancer Research Communications* and is on the editorial board for *Cell and Cancer Cell*.

# Panelist Bios



## **RICHARD SULLIVAN, MD, PhD**

Director, Institute for Cancer Policy, Professor of Cancer & Global Health  
*King's College, London*

Richard Sullivan is Professor of Cancer and Global Health at King's College London and Guy's Comprehensive Cancer Centre. He is director of the Institute of Cancer Policy and Director of the Centre for Conflict & Health Research at King's. He is an NCD advisor to World Health Organisation and World Bank. His global cancer research programs cover cancer systems strengthening, financing, political economy, global cancer surgery particularly virtual reality-enhanced surgical simulation training, as well as studies into social welfare and cancer care in conflict. He also directs a number of major research programs in conflict and health with a special focus on the Middle East, including Health Security Intelligence, Global Health Security and health systems strengthening in conflict. Professor Sullivan trained in surgery (urology) gaining his PhD in Biochemistry from University College London. Richard was formally Clinical Director of Cancer Research UK for nearly ten years and is a surgeon by background.



## **ERIC WINER, MD**

Director, *Yale Comprehensive Cancer Center*  
and Physician-in-Chief, *Smilow Cancer Hospital*

Dr. Eric Winer is the Director of Yale Cancer Center and President and Physician-in-Chief of Smilow Cancer Hospital Yale New Haven Health System as of February 1, 2022. He is also the Alfred Gilman Professor of Medicine and Pharmacology and Deputy Dean of Cancer Research at Yale School of Medicine. An internationally renowned expert in breast cancer, Dr. Winer has led and collaborated on innumerable clinical trials that have changed the face of the disease. His work is both broad and deep, and it has touched almost all aspects of breast cancer. Dr. Winer has long been an advocate of building teams consisting of scientists and clinicians to accelerate progress in cancer research and care.

Dr. Winer is Chair of the Board for the American Society of Clinical Oncology (ASCO) and a member of the Scientific Advisory Board of the Breast Cancer Research Foundation. For over a decade, he served as chief scientific advisor and chair of the Scientific Advisory Board for Susan G. Komen for the Cure. For the past six years he has co-lead the National Cancer Institute Breast Cancer Steering Committee. Dr. Winer has published over 350 original manuscripts and mentored over 30 fellows and junior faculty. In recognition of his mentoring impact, he was the recipient of the William Silen Lifetime Achievement in Mentoring Award from Harvard Medical School in 2020. He has also received numerous awards for his breast cancer research, most notably the William L. McGuire Memorial Lecture Award in 2016 at the San Antonio Breast Cancer Symposium.

Dr. Winer is an alumnus of both Yale College and Yale School of Medicine. After receiving his medical degree in 1983, he completed training in internal medicine and served as chief resident at Yale New Haven Hospital. He completed a fellowship in hematology/oncology at Duke University School of Medicine and served on the Duke faculty from 1989 to 1997. He then joined Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School where he has spent the last 24 years. Most recently, he held the Thompson Chair in Breast Cancer Research and served as chief clinical development officer, and senior vice president for medical affairs at Dana-Farber Cancer Institute, as well as Professor of Medicine at Harvard Medical School.



## **BRYONY WINN**

President Health Solutions  
*Elevance Health*

As President of Health Solutions, Bryony Winn is responsible for ensuring that the tens of millions of people in Elevance Health's family of health plans have access to high-quality, affordable care. Bryony is accountable for total cost of care, clinical strategy, building and managing relationships with care providers, advanced analytics, and more. Previously Chief Strategy Officer, Bryony was responsible for accelerating enterprise strategy for sustained growth.

Since joining Elevance Health in 2020 from Blue Cross and Blue Shield of North Carolina where she was Head of Strategy and Innovation, Bryony has developed strategic initiatives that determine which capabilities to bring to the company's members and how the company can best fulfill its mission of improving lives and communities. Improving the impact of Elevance Health's operations, she was a driving force behind the inclusion of community health and social drivers of health (e.g., food insecurity, health equity) into the core business strategy.

Outside of work, Bryony is involved with leading a variety of health-related institutions. In 2021, she joined the Fast Company Impact Council and was recognized as one of Fortune's 40 under 40 and Business Insider's 30 under 40 transforming healthcare. In 2019, Modern Healthcare named Bryony one of the nation's Top 25 Emerging Leaders, and she was one of 127 people in the world named to the Forum of Young Global Leaders by the World Economic Forum.

Prior to her leadership roles in the health insurance industry, Bryony was a partner in the Chicago office of McKinsey & Company. There, for nearly a decade, Bryony developed expertise about the intersection of healthcare in the public and private sectors. A native of Zimbabwe, Bryony began her career with McKinsey by providing strategic and operational counsel to a wide variety of clients across Europe and Africa. She relocated to the U.S. in 2011, where she advised numerous healthcare CEOs and state leaders seeking to improve systems of care and transform payment models.

Bryony was awarded a Master of Philosophy in international development from the University of Oxford, United Kingdom, where she was a Rhodes Scholar. She is a wife in a dual-career household and mom to three young children. She resides in Indianapolis, Indiana with her family.

Meyer Consulting is an international health care consulting firm that brings leading experts together in collaborative settings to build better health care solutions.





MEYER CONSULTING  
Phone (406) 531-5505  
[www.meyerconsultinginc.com](http://www.meyerconsultinginc.com)